StockNews.com cut shares of Atrion (NASDAQ:ATRI – Free Report) from a hold rating to a sell rating in a research note issued to investors on Monday.
Atrion Price Performance
Atrion stock opened at $399.83 on Monday. The firm has a 50 day simple moving average of $401.31 and a 200-day simple moving average of $364.59. The stock has a market capitalization of $703.70 million, a PE ratio of 36.25 and a beta of 0.60. Atrion has a 12-month low of $274.98 and a 12-month high of $643.48.
Atrion (NASDAQ:ATRI – Get Free Report) last released its earnings results on Thursday, February 29th. The medical instruments supplier reported $3.65 EPS for the quarter. Atrion had a net margin of 11.46% and a return on equity of 8.07%. The business had revenue of $43.58 million during the quarter.
Atrion Announces Dividend
Hedge Funds Weigh In On Atrion
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Copeland Capital Management LLC boosted its stake in shares of Atrion by 56.4% during the 4th quarter. Copeland Capital Management LLC now owns 86 shares of the medical instruments supplier’s stock valued at $33,000 after buying an additional 31 shares during the period. Quadrant Capital Group LLC acquired a new stake in shares of Atrion during the 4th quarter valued at $36,000. Harbor Investment Advisory LLC boosted its stake in shares of Atrion by 33.1% during the 4th quarter. Harbor Investment Advisory LLC now owns 189 shares of the medical instruments supplier’s stock valued at $72,000 after buying an additional 47 shares during the period. Tower Research Capital LLC TRC boosted its stake in shares of Atrion by 592.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 270 shares of the medical instruments supplier’s stock valued at $102,000 after buying an additional 231 shares during the period. Finally, SG Americas Securities LLC acquired a new stake in shares of Atrion during the 4th quarter valued at $108,000. Institutional investors and hedge funds own 66.19% of the company’s stock.
About Atrion
Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.
Featured Articles
- Five stocks we like better than Atrion
- Upcoming IPO Stock Lockup Period, Explained
- It’s Time to Buy Into the Super Micro Computer Stock Implosion
- How to Effectively Use the MarketBeat Ratings Screener
- Merger or Not, Albertson’s Companies is a Good Buy
- 5 Top Rated Dividend Stocks to Consider
- 3 Cheap Stocks That Shouldn’t Be So
Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.